Cáncer » Oncología Médica
Coordinador de Grupo
Guillermo López Vivanco
Doctor en Medicina
Jefe de Servicio Oncología Médica. HUC
Profesor asociado Unidad Docente Facultad de Medicina y Enfermería de la UPV/EHU, Dpto. Enfermería
OSI Eskerraldea Enkarterri Cruces
Miembros del Grupo
Josu Aurrekoetxea Oribe
Eider Azkona Uribelarrea
María Begoña Calvo Martínez
Sergio Carrera Revilla
Natalia Fuente Fernández
Eluska Iruarrizaga Ovejas
Gonzalo López de Argumedo Esnarrizaga
Juan Manuel Mañe Martínez
Ines Marrodan Ciordia
Alberto Muñoz Llarena
Itziar Rubio Etxebarria
Abigail Ruíz de Lobera Martínez
Aintzane Sancho Gutierrez
Irene Ugalde Martin
Líneas de Investigación
Actividades del Grupo
Publicaciones Científicas

Arriola E, Paredes-Lario A, García-Gomez R, Diz-Tain P, Constenla M, García-Girón C, et al. Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESS. Clin. Transl. Oncol. 2018; 20(10): 1261 - 1267. FI: 2,392(Q3). DOI: 10.1007/s12094-018-1855-y.

Conde E, Hernandez S, Martinez R, De Castro J, Collazo-Lorduy A, Jimenez B, et al. Evaluation of a Novel ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in NSCLC Patients. J. Thorac. Oncol. 2018; 13(10): 553 - 554. MEETING ABSTRACT.

Callejo-Goena A, Rubio-Etxebarria I, Sancho-Gutiérrez A, Azkuna-Sagarduy J, Lopetegi-Aizpurua A, López-Vivanco G. Infective endocarditis in a patient with metastatic colorectal cancer. Rev. Esp. Quim. 2018; 31(1): 75 - 77. FI: 0,605(Q4). LETTER.

Redondo A, Vazquez MR, Manso L, Gil MJG, Llinas IG, Garcia-Garre E, et al. Long-term response to first-line bevacizumab-based therapy in patients with metastatic breast cancer: results of the observational "LORENA" study. OncoTargets Ther.. 2018; 11: 5845 - 5852. FI: 2,656(Q2). DOI: 10.2147/OTT.S170303.

Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2018; 378(22): 2078 - 2092. FI: 79,258(Q1). DOI: 10.1056/NEJMoa1801005.

Provencio M, Nadal E, Insa A, Campelo RG, Huidobro GG, Domine M, et al. Phase II Study of Neo-Adjuvant Chemo/Immunotherapy for Resectable Stages IIIA Non-Small Cell Lung Cancer-Nadim Study-SLCG. J. Thorac. Oncol. 2018; 13(10): 320 - 320. MEETING ABSTRACT.

Garcia-Foncillas J, Tabernero J, Elez E, Aranda E, Benavides M, Camps C, et al. Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer. Br. J. Cancer. 2018; 119(12): 1464 - 1470. FI: 5,922(Q1). DOI: 10.1038/s41416-018-0293-5.

Carrera S, Sancho A, Azkona E, Azkuna J, Lopez-Vivanco G. Hereditary pancreatic cancer: related syndromes and clinical perspective. Hered Cancer Clin Pract. 2017;15:9. FI:1,590(Q4). DOI:10.1186/s13053-017-0069-6.

Chaib I, Karachaliou N, Pilotto S, Servat JC, Cai XT, Li XF, et al. Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in; EGFR-Mutant NSCLC. JNCI-Natl Cancer Inst. 2017;109:djx014 . FI:12,589(Q1). DOI:10.1093/jnci/djx014.

De Juan VC, Molla AI, Dols MC, Sureda BM, Lopez-Vivanco G, Rubio JC, et al. Neo-adjuvant chemo/immunotherapy for the treatment of resectable stage; IIIA non-small cell lung cancer (NSCLC): A phase II multicenter; exploratory study NADIM trial. Ann Oncol. 2017;28:1286TiP. FI:11,855(Q1). ABSTRACT

Foncillas JG, Tabernero J, Aguilar EA, Benavides M, Camps CJ, Lopez R, et al. First prospective multicenter real-world RAS mutation comparison between; OncoBEAM-based liquid biopsy and tissue analysis. Ann Oncol. 2017;28:129P. FI:11,855(Q1). ABSTRACT

Gonzalez MJE, de la Pena FA, Vazquez RM, Garcia-Saenz JA, Calvo EG, Manas JJI, et al. Retrospective observational study to evaluate the use of halaven plus; trastuzumab for the treatment of HER2 metastatic breast cancer (MBC) in Spain: HALATRUST study. Ann Oncol. 2017;28:307P. FI:11,855(Q1). ABSTRACT

Karachaliou N, Gimenez-Capitan A, Drozdowskyj A, Aldeguer E, Cao MG, Cardona AF, et al. Expression of genes associated with anti-viral response in EGFR mutant; non-small cell lung cancer (NSCLC). Ann Oncol. 2017;28:8P. FI:11,855(Q1). ABSTRACT

Karachaliou N, Chaib I, Cardona A, Lopez-Vivanco G, Vergnenegre A, Sanchez JM, et al. Co-Activation of STAT3 and YAP1 Signaling Pathways Limits EGFR Inhibitor Response in Lung Cancer. J Thorac Oncol. 2017;12:1216-17. FI:6,595(Q1). DOI:10.1016/j.jtho.2016.11.1714. ABSTRACT

Karachaliou N, Morales-Espinosa D, Vila MAM, Garde J, Baron F, Cobo M, et al. AZD9291 as 1st-Line Therapy for EGFR Mutant NSCLC Patients with Concomitant Pretreatment EGFR T790M Mutation. The AZENT Study. J Thorac Oncol. 2017;12:1074-5. FI:6,595(Q1). DOI:10.1016/j.jtho.2016.11.1503. ABSTRACT

Lopez-Vivanco G, Salvador J, Diez R, Lopez D, De Salas-Cansado M, Navarro B, De la Haba-Rodriguez J. Cost minimization analysis of treatment with intravenous or subcutaneous; trastuzumab in patients with HER2-positive breast cancer in Spain. Clin Transl Oncol. 2017;19:1454-61. FI:2,353(Q3). DOI:10.1007/s12094-017-1684-4.

Mane JM, Calvo B, Aresti U, Carrera S, Sancho A, Azkona E, et al. Epithelial ovarian cancer and primary peritoneal carcinomatosis in the elderly: what is our clinical practice?. Eur J Gynaecol Oncol. 2017;38:695-9. FI:0,692(Q4). DOI:10.12892/ejgo3674.2017.

Vazquez MR, Redondo A, Manso L, Gil M, Garau I, Perez-Carrion R, et al. Long-term responders to first-line bevacizumab-based therapy in metastatic breast cancer (MBC) patients: Results of the observational study LORENA. J Clin Oncol. 2017;35:e12563. FI:24,008(Q1). DOI:10.1200/JCO.2017.35.15_suppl.e12563. ABSTRACT

Arriola E, Paredes A, Gomez RG, Diz P, Constenla M, Girón CG, et al. 147P: Level of concordance between EGFR mutation status obtained from tissue/cytology and blood (plasma) for advanced non-small-cell lung cancer in Spain: ASSESS study. J Thorac Oncol. 2016;11:S122. FI:6,595(Q1). DOI:10.1016/S1556-0864(16)30257-X.

Cacicedo J, Fernandez I, Del Hoyo O, Gomez-Iturriaga A, Martinez-Indart L, Frias A, et al. Prognostic Value of Maximum Standardized Uptake Value Measured by Pretreatment 18F-FDG PET/CT in Locally Advanced Head and Neck Squamous Cell Carcinoma: Adding Value to Clinical Staging. Int J Radiat Oncol Biol Phys. 2016;96:E383. FI:5,133(Q1). ABSTRACT

Camps C, Albanell J, Antón A, Aranda E, Carrato A, Cassinello J, et al. Quality Indicators to Assure and Improve Cancer Care in Spain Using the Delphi Technique. J Natl Compr Canc Netw. 2016;14:553-8. FI:4,675(Q2).

Espinosa E, Soriano V, Malvehy J, Berrocal A, Martínez de Prado P, Quindós M, et al. Treatment patterns of adjuvant interferon-a2b for high-risk melanoma: a retrospective study of the Grupo Español Multidisciplinar de Melanoma - Prima study. Melanoma Res. 2016;26:278-83. FI:2,615(Q2). DOI:10.1097/CMR.0000000000000254.

González-Martín A, Alba E, Ciruelos E, Cortés J, Llombart A, Lluch A, et al. Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile. Curr Cancer Drug Targets. 2016;16:415-28. FI:2,992(Q3). DOI:10.2174/1568009615666150817121731.

Karachaliou N, Chaib I, Cai X, Li X, Cardona AF, Lopez-Vivanco G, et al. Poly-therapy with EGFR, STAT3 and Src-YAP1 signaling pathway inhibition; A breakthrough for EGFR mutant NSCLC. Ann Oncol. 2016;27:1188P. FI:11,855(Q1). DOI:10.1093/annonc/mdw382.2. ABSTRACT

Arrospide A, Soto-Gordoa M, Acaiturri T, Lopez-Vivanco G, Abecia LC, Mar J. Cost of Breast Cancer Treatment by Clinical Stage in the Basque Country, Spain. Rev Esp Salud Publica. 2015;89:93-97. FI:0,600(Q4).

Ayala F, Feijoo M, Martinez N, Gerico, JF, Gomez A, Sanchez P, et al. Clinical profile and prognosis of metastatic breast cancer (MBC) patients with long-lasting response to eribulin (E): Results of the EXTER study. J Clin Oncol. 2015;33:e12022 FI:20,982(Q1). ABSTRACT

Cacicedo J, Fernandez I, del Hoyo O, Dolado A, Gomez-Suarez J, Hortelano E, et al. Should PET/CT be implemented in the routine imaging work-up of locally advanced head and neck squamous cell carcinoma? A prospective analysis. Eur J Nucl Med Mol I. 2015;42:1378-1389. FI:5,537(Q1). DOI:10.1007/s00259-015-3071-0.

Capdevila J, Sevilla I, Alonso V, Aparicio LA, Jimenez P, Grande E, et al. Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis. BMC Cancer. 2015;15:495. FI:3,265(Q2). DOI:10.1186/s12885-015-1512-6.

Diaz-Rubio E, Anton A, Aranda E, Carrato A, Gascon P, Lopez-Vivancos G, et al. Developing standards and indicators for quality improvement for cancer patients in Spain. Eur J Cancer. 2015;51:156. FI:6,163(Q1). ABSTRACT

Doval D, Cinieri S, Bozcuk H, Pierga JY, Altundag K, Wang X, et al. Exploratory post hoc analyses of patient-reported outcomes (PROs) in the IMELDA randomized phase III trial: Maintenance bevacizumab (BEV) +/- capecitabine (CAP) after initial first-line BEV plus docetaxel (DOC) for HER2-negative metastatic breast can. Cancer Res. 2015;75:P2-12-16. FI:8,556(Q1). ABSTRACT

Garcia R, Moran T, Cardenal F, Alonso-Jaudenes G, Carcereny E, Pallares C, et al. BIM and SHP2 expression levels to predict clinical outcome to EGFR tyrosine kinase inhibitors (TKI) in EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p). J Clin Oncol. 2015;FI:20,982(Q1). ABSTRACT

Gonzalez-Pinto A, Martinez M, Garcia-Alocen A, Bermudez C, Lopez P. First bipolar episodes and functionality. Relation with depressive symptoms and inflammation. Bipolar Disord. 2015;17:125. FI:4,882(Q1). ABSTRACT

Karachaliou N, Codony-Servat J, Teixido C, Pilotto S, Drozdowskyj A, Codony-Servat C, et al. BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer. Sci Rep-Uk. 2015;5:17499 FI:5,228(Q1). DOI:10.1038/srep17499.

Lopez G, Carrera S, Rubio I, Azcona E, Sancho A, Calvo B, et al. Final results of a phase II study of bevacizumab, cisplatin and pemetrexed as first-line therapy for patients with advanced non squamous non small cell lung cancer.. J Clin Oncol. 2015;33:e19036.FI:20,982(Q1). ABSTRACT

Massuti B, Cobo M, Rodriguez-Paniagua JM, Ballesteros AI, Moran T, Arrabal R, et al. Randomized phase III trial of customized adjuvant chemotherapy (CT) according BRCA-1 expression levels in patients with node positive resected non-small cell lung cancer (NSCLS) SCAT: A Spanish Lung Cancer Group trial (Eudract:2007-000067-15; NCTgov:00478699). J Clin Oncol. 2015;33:7507.FI:20,982(Q1). ABSTRACT

Massuti B, Rodriguez-Paniagua JM, Cobo M, Arrabal R, Ballesteros I, Pun YW, et al. Results Ph III Trial Customized Adjuvant CT after Resection of NSCLC with Lymph Node Metastases SCAT: A Spanish Lung Cancer Group Trial. J THORAC ONCOL. 2015; 10: 180. FI: 5,040(Q1). ABSTRACT

Sancho A, Carrera S, Arietaleanizbeascoa M, Arce V, Mendizabal N, March AG, et al. Supervised physical exercise to improve the quality of life of cancer patients: the EFICANCER randomised controlled trial. BMC Cancer. 2015;15:40. FI:3,265(Q2). DOI:10.1186/s12885-015-1055-x.

Moran T, Wei J, Cobo M, Qian X, Domine M, Zou Z, et al; Spanish Lung Cancer Group; French Lung Cancer Group; Comprehensive Cancer Centre of Drum Tower Hospital in Nanjing.Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies(aEuro). Ann Oncol. 2014;25:2147-55. FI: 7,040(Q1)

Aresti U, Carrera S, Iruarrizaga E, Fuente N, Marrodan I, de Lobera AR, et al. Estrogen Receptor 1 Gene Expression and Its Combination with Estrogen Receptor 2 or Aromatase Expression Predicts Survival in Non-Small Cell Lung Cancer. PLoS One. 2014;9:e109659. FI: 3,234(Q1)

Uribarri M, Hormaeche I, Zalacain R, Lopez-Vivanco G, Martinez A, Nagore D, et al. A New Biomarker Panel in Bronchoalveolar Lavage for an Improved Lung Cancer Diagnosis. J Thorac Oncol. 2014;9:1504-12. FI: 5,282(Q1)

Martínez-García MA, Campos-Rodriguez F, Durán-Cantolla J, de la Peña M, Masdeu MJ, González M, et al; Spanish Sleep Network. Obstructive sleep apnea is associated with cancer mortality in younger patients. Sleep Med. 2014;15:742-8. FI: 3,154(Q2)

Carrera S, Buque A, Azkona E, Aresti U, Calvo B, Sancho A, et al. Epidermal growth factor receptor tyrosine-kinase inhibitor treatment resistance in non-small cell lung cancer: biological basis and therapeutic strategies. Clin Transl Oncol. 2014;16:339-50. FI: 2,077(Q3)

Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, et al; START trial team. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15:59-68. FI: 24,690(Q1)

Martin-Algarra S, Soriano V, Malvehy J, Berrocal A, Quindos M, Martinez Del Prado P, et al. Treatment patterns of adjunvant interferon ALFA-2B(IFN-alpha 2B) for high-risk melanoma. A retrospective study of the grupo espanol multidisciplinary de melanoma. (GEM). Ann Oncol. 2014;25(suppl 4):1123. FI: 7,040(Q1)

Cacicedo J, Del Hoyo O, Rodeno E, Fernandez I, Rodriguez O, Dolado A, et al. Utility Of 18F-Fluorodeoxyglucose Positron Emission Tomography (PET/CT) in the Staging and Treatment Plan Evaluation of Head and Neck Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys. 2014;90:552. FI: 4,258(Q1)

Lecumberri R, López Vivanco G, Font A, González Billalabeitia E, Gúrpide A, Gómez Codina J, Isla D, Galán A, Bover I, Domine M, Vicente V, Rosell R, Rocha E. Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: Resultsfromthe ABEL study. Thromb Res. 2013;132:666-70. FI: 3,133(Q2)

Pivot X, Gligorov J, Müller V, Barrett-Lee P, Verma S, Knoop A, Curigliano G, Semiglazov V, López-Vivanco G, Jenkins V, Scotto N, Osborne S, Fallowfield L; PrefHerStudyGroup. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol. 2013;14:962-70. FI: 25,117(Q1)

Castellano D, Garcia del Muro X, Climent MA, Maroto P, Perez-Gracia JL, Lopez-Vivanco G, Zhang K, Fly K, Hariharan S, Anton-Aparicio L. Sunitinib expanded-access trial in metastatic renal cell carcinoma (mRCC) - final results from Spain. Eur  J Cancer.  2013; 49: 666.FI: 5,061(Q1)

Buqué A, Aresti U, Calvo B, ShMuhialdin J, Muñoz A, Carrera S, Azkona E, Rubio I, López-Vivanco G. Thymidylate Synthase Expression Determines Pemetrexed Targets and Resistance Development in Tumour Cells. PLoS One. 2013;8:e63338. FI: 3,730(Q1)

De Cock E, Semiglazov V, Lopez Vivanco G, Verma S, Pivot X, Gligorov J, Hauser N, Urspruch A, Kritikou P, Knoop A. Time savings with trastuzumab subcutaneous vs intravenous administration: a time and motion study. Breast 2013;22: S88.  FI: 1,967(Q2).

E Alba, E Ciruelos, R López, JM López-Vega, A Lluch, M Martín, et al.  Cost–Utility Analysis of NanopA Albumin-Bound Paclitaxel versus Paclitaxel in Monotherapy in Pretreated Metastatic Breast Cancer in Spain. Expert Rev Pharmacoeconomics Outcomes Res 2013;13:381-91.

Tesis
Buqué Martínez A, López Vivanco G (dirección). Effect of multitargeted antifolate on human metastatic melanoma cell lines. Molecular pathways and resistance mechanisms.